FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies - FDA Press Releases

FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting

from FDA Press Releases RSS Feed https://ift.tt/2PHYHXB
via IFTTT